Neurocrine Biosciences, a San Diego-based drug developer, said Tuesday an experimental schizophrenia medicine that it recently licensed from Takeda has failed a key test.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,